Guest guest Posted June 29, 2004 Report Share Posted June 29, 2004 Hello Dave and others: I was mainly inquiring about the prevalence of small duct PSC and IBD, rather than classic PSC and IBD. From what I've read, in order to confirm a diagnosis of small duct PSC, the patient MUST also have IBD. I'm aware that there is a minority of classic PSC cases where there is no IBD, but small duct PSC apparently coexists with IBD 100% of the time. Please let me know if anyone finds out otherwise. Husband Fred, PSC (small duct, we think!) 03/04 Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 29, 2004 Report Share Posted June 29, 2004 Hi ; Sorry I didn't fully answer your question earlier. I have not found anything that would contradict your conclusion about the association between small duct PSC and IBD. For example, Kim, Ludwig and Lindor (2000) write .... " Isolated small duct PSC is diagnosed if patients have inflammatory bowel disease, biopsy features compatible with PSC, but a normal cholangiogram. " : Kim WR, Ludwig J, Lindor KD 2000 Variant forms of cholestatic diseases involving small bile ducts in adults. Am. J. Gastroenterol. 95: 1130-1138. So, is Fred an exception, with small duct PSC without IBD? Or is it possible that Fred has a mild form of IBD that has not yet been diagnosed, perhaps like the form(s) of IBD described in the Uchida et al paper posted earlier? The health benefits of checking for IBD might be that, if found, it would be possible to get this into remission early, and perhaps help prevent colorectal cancer from developing over the long-term (?): Allgayer H 2003 Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment. Pharmacol. Ther. 18 Suppl. 2: 10-14. Best regards, Dave Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 29, 2004 Report Share Posted June 29, 2004 Thanks for the response and the references, Dave. Your first reference about the IBD and small duct PSC connection is the one I read. I am surprised that Fred's hepatologist didn't recommend a colonoscopy, since there is a much higher risk of colon cancer with untreated UC, and most PSC patients have some form of IBD. Do I recall that Urso protects against colon cancer? Or does it mainly protect against bile duct and liver cancer? Anyone know off the top of their head? Husband Fred PSC 03/04 Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 29, 2004 Report Share Posted June 29, 2004 Yes, , there are some reports that ursodiol (UCDA) protects against colon cancer. One of them is shown below: Gastroenterology. 2003 Apr;124(4):889-93 Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Division of Gastroenterology and Hepatology and Division of Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA. pardi.darrell@... BACKGROUND & AIMS: Ursodeoxycholic acid (UDCA) has shown effectiveness as a colon cancer chemopreventive agent in preclinical studies. In addition, a recent report suggests that it also may decrease the risk for developing colorectal dysplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We sought to evaluate the effect of UDCA on colorectal neoplasia in a group of patients with UC and PSC enrolled in a randomized, placebo-controlled trial. METHODS: From a prior, randomized, placebo-controlled trial of UDCA therapy in PSC at our center, we followed-up patients with concomitant UC to assess the effect of UDCA on the development of colorectal dysplasia and cancer as compared with placebo. ReESULTS: Fifty-two subjects were followed- up for a total of 355 person-years. Those originally assigned to receive UDCA had a relative risk of 0.26 for developing colorectal dysplasia or cancer (95% confidence interval, 0.06-0.92; P = 0.034). Many of the patients originally assigned to the placebo group eventually received open-label UDCA. Assigning these patients to the UDCA group from the time they began active therapy did not change the magnitude of the protective effect (relative risk, 0.26; 95% confidence interval, 0.07-0.99; P = 0.049). CONCLUSIONS: UDCA significantly decreases the risk for developing colorectal dysplasia or cancer in patients with UC and PSC. Publication Types: Clinical Trial Randomized Controlled Trial PMID: 12671884 Best regards, Dave Quote Link to comment Share on other sites More sharing options...
Guest guest Posted June 29, 2004 Report Share Posted June 29, 2004 , You recall correctly, although " protects " is probably too strong a word. I would say " Urso reduces the incidence of colon cancer, " based on the reported reduced incidence of pre-cancerous polops in PSC patients being treated with URSO relative to those that went untreated. Tim R > Do I recall that Urso protects against colon cancer? Or does it > mainly protect against bile duct and liver cancer? Anyone know off > the top of their head? > > > Husband Fred PSC 03/04 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.